Semaglutide single‐dose pen‐injector: Post hoc analysis of summative usability testing for weight management

Subcutaneous semaglutide, at a 2.4 mg once‐weekly maintenance dose, is approved in the United States for weight management in individuals with a body mass index (BMI) of 30 kg/m(2) or higher, or with a BMI of 27 kg/m(2) or higher and at least one obesity‐related co‐morbidity. To investigate the usab...

Descripción completa

Detalles Bibliográficos
Autores principales: Klonoff, David C., Bassock, Stephanie, Engels, Ella, Frederiksen, Marie, Marber, Matthew, Qvist, Marianne, Sparre, Thomas, Snitker, Søren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292194/
https://www.ncbi.nlm.nih.gov/pubmed/34338402
http://dx.doi.org/10.1111/dom.14509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292194/
https://www.ncbi.nlm.nih.gov/pubmed/34338402
http://dx.doi.org/10.1111/dom.14509

Ejemplares similares